Provided by Tiger Fintech (Singapore) Pte. Ltd.

Durect

0.7366
-0.0288-3.76%
Volume:11.10K
Turnover:8.19K
Market Cap:22.87M
PE:-1.10
High:0.7665
Open:0.7300
Low:0.7300
Close:0.7654
Loading ...

Q3 2024 DURECT Corp Earnings Call

Thomson Reuters StreetEvents
·
14 Nov 2024

Durect Corp (DRRX) Q3 2024 Earnings Call Highlights: Revenue Growth Amid Cost Reductions and ...

GuruFocus.com
·
14 Nov 2024

DURECT Corporation’s Q3 2024 Financial Highlights

TIPRANKS
·
14 Nov 2024

DURECT Corp reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
14 Nov 2024

Durect (DRRX) Reports Q3 Loss, Misses Revenue Estimates

Zacks
·
14 Nov 2024

Durect: Q3 Earnings Snapshot

Associated Press Finance
·
14 Nov 2024

Durect Q3 2024 GAAP EPS $(0.14) Beats $(0.17) Estimate, Sales $1.927M Miss $1.975M Estimate

Benzinga
·
14 Nov 2024

DURECT Corp expected to post a loss of 17 cents a share - Earnings Preview

Reuters
·
12 Nov 2024

DURECT Corp expected to post a loss of 17 cents a share - Earnings Preview

Reuters
·
09 Nov 2024

DURECT Corporation to Announce Third Quarter 2024 Financial Results and Provide a Business Update

THOMSON REUTERS
·
07 Nov 2024

Durect Corp (DRRX) Q2 2024 Earnings Call Highlights: Revenue Growth and Strategic Advances Amid ...

GuruFocus.com
·
10 Oct 2024

Durect Corp Annual Meeting Decisions and Shareholder Votes

TIPRANKS
·
27 Sep 2024

Durect agreement on larsucosterol trial ‘a major positive,’ says Northland

TIPRANKS
·
26 Sep 2024

Durect (DRRX) Receives a Hold from H.C. Wainwright

TIPRANKS
·
26 Sep 2024

BRIEF-Durect Corporation Announces Phase 3 Registrational Trial Design For Larsucosterol In Alcohol-Associated Hepatitis

Reuters
·
25 Sep 2024

DURECT Corporation Announces Phase 3 Registrational Trial Design for Larsucosterol in Alcohol-Associated Hepatitis

THOMSON REUTERS
·
25 Sep 2024